Ideaya Biosciences, Inc. progresses trials for uveal melanoma and solid tumors, with key upcoming data milestones. Click for ...

The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...

Welcome to Zymeworks first-quarter 2025 results conference call and webcast. (Operator Instructions) I would now like to turn the conference over to Shrinal Inamdar, Senior Director of Investor ...